Mifepristone, a Glucocorticoid Receptor Antagonist, Reduced HbA1c and Body Weight in Difficult-to-control Type 2 Diabetes with Hypercortisolism: The CATALYST Prevalence and Treatment Trial
Summary
- Hypercortisolism prevalence was 23.8% among the 1,057 CATALYST participants
- Baseline characteristics that increased odds of having hypercortisolism:
- higher medication burden for glucose control, hypertension, lipids, and psych disease
- presence of cardiovascular disease
- In patients with difficult-to-control type 2 diabetes and hypercortisolism, mifepristone significantly reduced HbA1c (1.32%) and body weight (5.1 kg)